Role of bone-modifying agents in advanced cancer | Zendy

Danielle Desautels | Zendy; Craig Harlos | Zendy; Katarzyna J. Jerzak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Role of bone-modifying agents in advanced cancer

Author(s) -

Danielle Desautels,

Craig Harlos,

Katarzyna J. Jerzak

Publication year - 2019

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm.2019.08.07

Subject(s) - medicine , denosumab , spinal cord compression , multiple myeloma , osteoclast , bone pain , osteonecrosis of the jaw , cancer , oncology , bone density conservation agents , bisphosphonate , osteoblast , osteoporosis , bone density , spinal cord , biochemistry , chemistry , receptor , psychiatry , in vitro

Bone lesions from metastatic solid tumors and multiple myeloma (MM) represent an important source of morbidity in patients with incurable malignancies. Dysregulation of osteoclast and osteoblast activity caused by tumor cells in the bone microenvironment weakens the structural integrity of bone and predisposes to skeletal-related events (SREs), which can include severe bone pain, pathologic fracture, spinal cord compression and hypercalcemia. In order to reduce the risk of these complications, the supportive treatment of patients with bone lesions from advanced cancer typically includes the use of bone-modifying agents (BMAs), specifically bisphosphonates and denosumab. The choice of specific agent, dosing schedule and duration of therapy should be individualized by taking into account disease characteristics, medication side-effect profiles and patient preferences.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research